Novartis’ Cosentyx heads for fourth indication after supportive data in early ankylosing spondylitis

Novartis’ Cosentyx could be heading for a fourth indication after the company published late-stage trial data showing it improved symptoms in patients with ankylosing spondylitis, whose disease does not show on X-rays.